DK2670843T3 - Multivalente vacciner til rabiesvirus og filovirus - Google Patents

Multivalente vacciner til rabiesvirus og filovirus Download PDF

Info

Publication number
DK2670843T3
DK2670843T3 DK12702953.6T DK12702953T DK2670843T3 DK 2670843 T3 DK2670843 T3 DK 2670843T3 DK 12702953 T DK12702953 T DK 12702953T DK 2670843 T3 DK2670843 T3 DK 2670843T3
Authority
DK
Denmark
Prior art keywords
vaccine
rabv
filovirus
rabies virus
virus
Prior art date
Application number
DK12702953.6T
Other languages
English (en)
Inventor
Joseph E Blaney
Jason Paragas
Peter Jahrling
Reed Johnson
Mathias Schnell
Original Assignee
Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services filed Critical Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services
Application granted granted Critical
Publication of DK2670843T3 publication Critical patent/DK2670843T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (15)

1. Rekombinant rabiesvirusvektor omfattende en nukleotidsekvens der koder for det mindst ene filovirus-glycoprotein eller et immunogent fragment deraf.
2. Rekombinant rabiesvirusvektor ifølge krav 1, hvor det mindst ene filovirus-glycoprotein er Ebolavirus-glycoprotein.
3. Værtscelle omfattende den rekombinante rabiesvirusvektor ifølge et hvilket som helst af kravene 1-2.
4. Isolerede virioner fremstillet fra værtsceller inficeret med en rekombinant rabiesvirusvektor ifølge et hvilket som helst af kravene 1-2.
5. Multivalent vaccine der er effektiv til at beskytte mod både et rabies- og filovirus, omfattende en rekombinant rabiesvirusvektor der udtrykker mindst et filovirusglycoprotein eller et immunogent fragment deraf.
6. Multivalent vaccine ifølge krav 5, hvor det mindst ene filovirusglycoprotein er Ebola-glycoprotein.
7. Værtscelle omfattende den multivalente vaccine ifølge et hvilket som helst af kravene 5-6.
8. Isolerede virioner fremstillet fra en værtscelle inficeret med den multivalente vaccine ifølge krav 7.
9. Vaccinesammensætning omfattende én eller flere multivalente vacciner ifølge et hvilket som helst af kravene 5-8 og en farmaceutisk acceptabel bærer.
10. Virusvaccine omfattende en svækket rekombinant rabiesvirusvektor der udtrykker Ebola-glycoproteinet, hvor virusvaccinen beskytter både mod en rabiesvirusinfektion og en Ebolavirus-infektion.
11. Terapeutisk effektiv mængde af en multivalent vaccine omfattende en rekombinant rabiesvirusvektor der udtrykker mindst et filovirus glycoprotein eller et immunogent fragment deraf til anvendelse i en fremgangsmåde til at inducere en immunresponsbeskyttelse mod et filovirus og et rabiesvirus hos et individ.
12. Terapeutisk effektiv mængde af en multivalent vaccine omfattende en rekombinant rabiesvirusvektor der udtrykker mindst et filovirus-glycoprotein eller et immunogent fragment deraf til anvendelse i en fremgangsmåde til at inducere neutraliserende antistoffer mod et filovirus og/eller et rabiesvirus hos et individ inficeret med eller som er blevet eksponeret for hvert af eller begge af disse virua.
13. Terapeutisk effektiv mængde af en multivalent vaccine omfattende en rekombinant rabiesvirusvektor der udtrykker mindst et filovirusglycoprotein eller et immunogent fragment deraf, hvor vaccinen inducerer et effektivt immunrespons mod et eller begge af disse vira til anvendelse i en fremgangsmåde til behandling af et individ inficeret med et filovirus og/eller et rabiesvirus.
14. Levende, replikations-kompetent, rabiesvirus-baseret vektor der udtrykker et Ebola-glycoprotein.
15. Levende, replikations-deficient, rabiesvirus-baseret vektor der udtrykker et Ebola-glycoprotein.
DK12702953.6T 2011-02-03 2012-02-02 Multivalente vacciner til rabiesvirus og filovirus DK2670843T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439046P 2011-02-03 2011-02-03
PCT/US2012/023575 WO2012106490A1 (en) 2011-02-03 2012-02-02 Multivalent vaccines for rabies virus and filoviruses

Publications (1)

Publication Number Publication Date
DK2670843T3 true DK2670843T3 (da) 2015-01-05

Family

ID=45567153

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12702953.6T DK2670843T3 (da) 2011-02-03 2012-02-02 Multivalente vacciner til rabiesvirus og filovirus

Country Status (6)

Country Link
US (1) US10849975B2 (da)
EP (1) EP2670843B1 (da)
CA (1) CA2826594C (da)
DK (1) DK2670843T3 (da)
ES (1) ES2528472T3 (da)
WO (1) WO2012106490A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102146904B1 (ko) * 2012-04-12 2020-08-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
US20150110857A1 (en) * 2013-10-22 2015-04-23 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
KR20190062617A (ko) * 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
HRP20240163T1 (hr) 2014-09-03 2024-04-12 Bavarian Nordic A/S Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
US10640549B2 (en) 2014-10-17 2020-05-05 University Of Virginia Patent Foundation Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein
US10695417B2 (en) * 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
EP4104854A3 (en) * 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
WO2022098656A1 (en) * 2020-11-03 2022-05-12 Thomas Jefferson University Gene shuffled lyssavirus vaccine
EP4263825A1 (en) * 2021-02-19 2023-10-25 Beam Therapeutics, Inc. Recombinant rabies viruses for gene therapy
CN114958919B (zh) * 2022-05-09 2023-05-09 军事科学院军事医学研究院军事兽医研究所 狂犬病病毒重组丝状病毒或沙粒病毒假病毒及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5015580A (en) 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1995019799A1 (en) 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
CA2200952C (en) 1994-09-30 2006-04-11 Inex Pharmaceuticals Corp. Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
EP1489184A1 (en) 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
JP4340330B2 (ja) 1996-05-24 2009-10-07 アイシー‐ヴェック・リミテッド トランスフェクション剤としてのポリカチオン性ステロール誘導体
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US6110745A (en) 1997-07-24 2000-08-29 Inex Pharmaceuticals Corp. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
ATE356202T1 (de) 1998-11-27 2007-03-15 Intervet Int Bv Attenuierte stabile tollwutvirusmutante und lebende impfstoffe
AU3703100A (en) 1999-02-22 2000-09-14 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US6200599B1 (en) 1999-10-07 2001-03-13 The Regents Of The University Of California Ortho ester lipids
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US20020012998A1 (en) 2000-03-29 2002-01-31 Igor Gonda Cationic liposomes
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
MXPA03008864A (es) 2001-03-26 2004-12-06 Johnson & Johnson Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico.
US20020192274A1 (en) 2001-03-26 2002-12-19 Ponnappa Biddanda C. pH sensitive liposomal drug delivery
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
DE60208854T2 (de) 2001-04-23 2006-08-17 Akzo Nobel N.V. Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe
CA2445947A1 (en) 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
EP1434862A4 (en) 2001-07-20 2005-04-06 Univ Georgia Res Found NUCLEOPROTEIC MUTATION-RELATED VIRUS AT A PHOSPHORYLATION SITE FOR OBTAINING A VACCINE AGAINST RABIES AND GENE THERAPY IN THE CENTRAL NERVOUS SYSTEM
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
DE10152145A1 (de) 2001-10-19 2003-05-22 Novosom Ag Stabilisierung von Liposomen und Emulsionen
WO2003057190A1 (en) 2001-12-31 2003-07-17 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
EP1478341A4 (en) 2002-01-09 2009-05-20 Transave Inc EFFICIENT ENCAPSULATION OF NUCLEIC ACIDS IN MEDIUM SIZE LIPOSOMES
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
AU2003233464A1 (en) 2002-03-29 2003-10-13 Bristol-Myers Squibb Corporation Lipid mediated screening of drug candidates for identification of active compounds
WO2009116982A2 (en) 2007-12-18 2009-09-24 Trustees Of Boston University Pre-or post-exposure treatment for filovirus or arenavirus infection

Also Published As

Publication number Publication date
CA2826594A1 (en) 2012-08-09
EP2670843A1 (en) 2013-12-11
CA2826594C (en) 2019-09-17
EP2670843B1 (en) 2014-10-29
US10849975B2 (en) 2020-12-01
ES2528472T3 (es) 2015-02-10
US20140212434A1 (en) 2014-07-31
WO2012106490A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
DK2670843T3 (da) Multivalente vacciner til rabiesvirus og filovirus
US20220072697A1 (en) Multivalent vaccines for rabies virus and coronaviruses
US11241493B2 (en) Coronavirus vaccine
CA3171219A1 (en) Compositions and methods for inducing immune responses
ES2535310T3 (es) Atenuación sinérgica del virus de la estomatitis vesicular, vectores del mismo y composiciones inmunogénicas del mismo
US11964012B2 (en) Coronavirus vaccine
JP2023513611A (ja) Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用
US20240156940A1 (en) Replication-deficient modified vaccinia ankara (mva) expressing marburg virus glycoprotein (gp) and matrix protein (vp40)
McKenna et al. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases
US20230190917A1 (en) Viral vaccine vector for immunization against a betacoronavirus
Kopecky-Bromberg et al. Recombinant vectors as influenza vaccines
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
EP1200563B1 (en) Attenuated influenza virus useful as vaccine
US20140255444A1 (en) Compositions and methods for treating ebola virus infection
US11274282B2 (en) Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
Bonilla A review on the Ebola virus, outbreak history and the current research tools to control the disease
WO2023091988A1 (en) Expression of the spike s glycoprotein of sars-cov-2 from avian paramyxovirus type 3 (apmv3)
Vugt Filoviridae: a minireview and the latest developments in vaccines.